Previous Pause Next
Home >> News Center >> Clinical Trials >>
Landmark Study Shows that Adding Rivaroxaban to Standard Antiplatelet Therapy Significantly Reduced Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome PDF Print E-mail
User Rating :  / 0
Tuesday, 15 November 2011 06:43

Rivaroxaban Used in Combination with Standard Therapy Reduced Cardiovascular Death by Over 30%

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that adding oral rivaroxaban to standard antiplatelet therapy significantly reduced the composite primary efficacy endpoint of cardiovascular-related deaths, heart attacks or strokes in patients with acute coronary syndrome (ACS) compared to those receiving standard therapy alone. Results from the pivotal Phase 3 ATLAS ACS 2 TIMI 51 trial presented today at the American Heart Association Scientific Sessions and published in the New England Journal of Medicine also showed that rivaroxaban significantly increased rates of major bleeding, but did not create an excess risk of fatal bleeding over standard therapy alone.

“The clinical benefit of giving rivaroxaban in combination with standard antiplatelet therapy seen in ATLAS TIMI 51 is welcome, and could lead to significant improvement in the management of patients with acute coronary syndrome,” said Eugene Braunwald, M.D., Distinguished Hersey Professor of Medicine at Harvard Medical School and Founding Chairman of the Thrombolysis In Myocardial Infarction (TIMI) Study Group, Brigham and Women’s Hospital.

ACS is a complication of coronary heart disease, which is the leading cause of death in the U.S. and one of the most prevalent non-communicable diseases in the world. ACS occurs when a blood clot blocks a coronary artery, reducing blood supply to the heart. This disruption of blood flow can directly cause a heart attack, or unstable angina, a condition signifying that a heart attack may soon occur. Each year, an estimated 1.2 million patients in the U.S. are discharged from the hospital with a primary or secondary diagnosis of ACS.

Results from the ATLAS ACS 2 TIMI 51 study showed that both 2.5 or 5 mg of rivaroxaban dosed twice daily (BID) in addition to standard therapy — low-dose aspirin with or without a thienopyridine such as clopidogrel — was superior to standard therapy alone in the primary efficacy endpoint of preventing secondary cardiovascular events (cardiovascular death, myocardial infarction or stroke) in patients with ACS [combined doses 8.9% vs. 10.7%¹ (P=0.008), Relative Risk Reduction (RRR) = 16%]. Additionally, rivaroxaban significantly reduced stent thrombosis compared with placebo [2.3% vs. 2.9% (P=0.02)].

Patients dosed with 2.5 mg BID of rivaroxaban showed a significant reduction in risk of the composite primary endpoint [9.1% vs. 10.7% (P=0.02)], driven by a significant 34% RRR in the rate of cardiovascular death [2.7% vs. 4.1% (P=0.002)]. There was also a significant reduction in deaths from any cause [2.9% vs. 4.5% (P=0.002)]. The 5 mg BID dose of rivaroxaban also significantly reduced the risk of the primary efficacy endpoint in the study [8.8% vs. 10.7% (P=0.03)].

The principal safety endpoint for the study was TIMI major bleeding events not associated with coronary artery bypass graft (CABG) surgery. In patients receiving rivaroxaban and standard therapy, rates were low overall, yet statistically significantly increased versus those treated with standard therapy plus a placebo [2.1% vs. 0.6% (P<0.001)]. Similarly, rivaroxaban exhibited higher rates of TIMI major bleeding events not associated with CABG surgery at both the 2.5 and 5 mg BID doses compared to placebo [1.8% vs. 0.6% (P<0.001) and 2.4% vs. 0.6% (P<0.001), respectively]. Importantly, these differences were not associated with an excess risk of fatal bleeding. Other treatment-emergent adverse events were generally balanced across treatment groups.

“For more than a decade ACS patients have been effectively treated with a low-dose aspirin given in combination with a thienopyridine to help reduce their risk of a recurrent cardiovascular event. This study showed that by adding the oral Factor Xa inhibitor rivaroxaban to standard therapy, this risk is greatly reduced, resulting in a significant reduction in mortality,” said C. Michael Gibson, M.D., senior investigator of the TIMI Study Group, Harvard Medical School, and the Principal Investigator in the ATLAS ACS studies of rivaroxaban. “If the data from ATLAS ACS 2 TIMI 51 were extrapolated into clinical practice, we could potentially see one life saved for every 56 patients treated with this combination of therapies over a two year period.”

The U.S. Food and Drug Administration (FDA) had previously granted rivaroxaban “fast track” designation for this indication. Fast Track designation allows the FDA to expedite review of drugs for serious or life-threatening conditions that demonstrate the potential to address unmet medical needs. Products in a fast track drug development program are eligible for priority review, but the FDA will only make their final determination upon review of the results.

“Results like these with a novel oral anticoagulant are unprecedented in acute coronary syndrome research,” said Peter M. DiBattiste, M.D., Global Therapeutic Area Head, Cardiovascular and Metabolism, J&JPRD. “Adding rivaroxaban to standard therapy has the potential to significantly improve outcomes for patients, and we look forward to submitting these results to the FDA before the end of the year.”

The ATLAS ACS 2 TIMI 51 (Anti-Xa Therapy to Lower cardiovascular events in Addition to aspirin with/without thienopyridine therapy in Subjects with Acute Coronary Syndrome) study was designed to test the efficacy of rivaroxaban compared to placebo in preventing cardiovascular death, heart attack or stroke in ACS patients. Patients were given standard antiplatelet therapy — low-dose aspirin with or without a thienopyridine such as clopidogrel — plus rivaroxaban dosed at 2.5 or 5 mg BID, or a placebo. Of the 15,526 patients randomized into the study, 93% received aspirin and thienopyridine in addition to rivaroxaban or placebo, and the balance were treated with aspirin and rivaroxaban or placebo.

The double blind, randomized, placebo-controlled study was coordinated by the TIMI Study Group and Brigham and Women’s Hospital and Harvard Medical School and was funded and led by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and Bayer HealthCare.

About Rivaroxaban
XARELTO® is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in people undergoing knee or hip replacement surgery, and for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. There are limited data on the relative effectiveness of XARELTO® and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well-controlled. XARELTO® belongs to a group of medicines called anticoagulants, and works by blocking the blood clotting Factor Xa, thereby reducing the tendency to form clots.

XARELTO® was the fifth New Drug Application approved by the U.S. FDA from the Janssen Pharmaceutical Companies in 2011.

Additionally, XARELTO® is being evaluated for the prevention and treatment of a broad range of disorders in which blood clotting plays a major role. The extensive program of clinical trials evaluating rivaroxaban makes the compound the most studied oral, Factor Xa inhibitor in the world today. By the time of its completion, more than 75,000 patients will have participated in the rivaroxaban clinical development program. Rivaroxaban is being developed jointly by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and Bayer HealthCare.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) is one of the Janssen Pharmaceutical Companies of Johnson & Johnson, the world’s most broadly based producer of health care products. J&JPRD is headquartered in Raritan, N.J., and has facilities throughout Europe, the United States and Asia. J&JPRD is actively involved in drug discovery and development within a variety of therapeutic areas, including Cardiovascular and Metabolism, Central Nervous System, Immunology, Oncology and Virology, to address unmet medical needs worldwide. More information can be found at


Add comment  |   Add to my library  |  Forward this article

login to leave comment